LifeStance Health Group, Inc. (NASDAQ:LFST) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of LifeStance Health Group, Inc. (NASDAQ:LFST) have received an average recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, five have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $9.00.

A number of equities analysts have recently commented on LFST shares. Weiss Ratings reissued a “sell (d-)” rating on shares of LifeStance Health Group in a research report on Monday, December 29th. Zacks Research cut shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 5th. UBS Group increased their price objective on shares of LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Wall Street Zen cut shares of LifeStance Health Group from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, BTIG Research increased their target price on LifeStance Health Group from $10.00 to $11.00 and gave the company a “buy” rating in a report on Monday.

Insider Buying and Selling

In other LifeStance Health Group news, insider Ann Varanakis sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $6.90, for a total transaction of $345,000.00. Following the completion of the transaction, the insider directly owned 315,610 shares in the company, valued at approximately $2,177,709. This trade represents a 13.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Lisa K. Miller sold 57,240 shares of the business’s stock in a transaction on Friday, November 21st. The stock was sold at an average price of $6.43, for a total value of $368,053.20. Following the completion of the transaction, the insider directly owned 261,292 shares of the company’s stock, valued at approximately $1,680,107.56. This trade represents a 17.97% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 327,326 shares of company stock worth $2,259,317 in the last 90 days. Company insiders own 6.60% of the company’s stock.

Institutional Investors Weigh In On LifeStance Health Group

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. AustralianSuper Pty Ltd purchased a new position in shares of LifeStance Health Group in the third quarter worth approximately $17,056,000. Vanguard Group Inc. boosted its stake in LifeStance Health Group by 21.1% in the 4th quarter. Vanguard Group Inc. now owns 17,700,041 shares of the company’s stock worth $124,608,000 after purchasing an additional 3,086,506 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in LifeStance Health Group by 62.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company’s stock worth $26,363,000 after purchasing an additional 1,839,465 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in LifeStance Health Group by 27.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 8,363,607 shares of the company’s stock valued at $45,998,000 after purchasing an additional 1,790,694 shares during the period. Finally, Integral Health Asset Management LLC acquired a new stake in LifeStance Health Group during the 3rd quarter valued at $8,250,000. 85.50% of the stock is currently owned by institutional investors and hedge funds.

LifeStance Health Group Trading Down 1.0%

Shares of NASDAQ:LFST opened at $7.11 on Wednesday. The business’s 50 day moving average price is $7.00 and its 200-day moving average price is $5.86. LifeStance Health Group has a 1 year low of $3.74 and a 1 year high of $8.30. The firm has a market capitalization of $2.77 billion, a price-to-earnings ratio of -237.00 and a beta of 1.12. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.58 and a quick ratio of 1.58.

LifeStance Health Group (NASDAQ:LFST) last issued its earnings results on Wednesday, November 5th. The company reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.03. LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. The business had revenue of $363.81 million during the quarter, compared to analysts’ expectations of $355.06 million. During the same period in the prior year, the business earned ($0.02) earnings per share. The company’s quarterly revenue was up 16.3% compared to the same quarter last year. On average, equities research analysts forecast that LifeStance Health Group will post -0.18 earnings per share for the current fiscal year.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.